1282480-10-7

Upstream product

• 82560-12-1 3-tert-butyl-1H-pyrazole-5-amine 
• 329-59-9 4-fluoro-3-nitro-benzoic acid methyl ester 
• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 59997-51-2 trimethylacetylacetonitrile 
• 1020210-39-2 methyl 4-[(3-tert-butyl-1H-pyrazol-5-yl)amino]-3-nitrobenzoate 
• 1020210-41-6 methyl 3-amino-4-[(5-tert-butyl-1H-pyrazol-3-yl)amino]-3-nitrobenzoate 
• 1122-91-4 4-bromo-benzaldehyde 

Relevant academic research and scientific papers

Methyl 2-(4-bromo-phenyl)-1-(5-tert-butyl-1H-pyrazol-3-yl)-1H-benz- imidazole-5-carboxyl-ate: A hydrogen-bonded chain of edge-fused centrosymmetric rings

In the title compound, C22H21BrN4O 2, the imidazole and pyrazole rings are almost orthogonal to each other, but the ester unit is effectively coplanar with the adjacent aryl rings. The mol-ecules are linked into a chain of edge-fused centrosymmetric rings by a combination of N - H...O and C - H...π(arene) hydrogen bonds.

Synthesis of novel 1,2,5-trisubstituted benzimidazoles as potential antitumor agents

Novel methyl 1-(5-tert-butyl-1H-pyrazol-3-yl)-2-(aryl)-1H-benzo[d] imidazole-5-carboxylates 11 were synthesized by following a four-step strategy involving a nucleophilic aromatic displacement (SNAr) and a solvent free approach as key steps for the formation of the desired products. Structure of intermediates and products were confirmed by X-ray diffraction as well as the tautomeric rearrangement suffered by the pyrazole moiety during the curse of the final cyclization process. Several of the obtained compounds were screened by the US National Cancer Institute (NCI) for their ability to inhibit 60 different human tumor cell lines. Products 11b and 11n exhibited the highest activity against a range of cancer cell lines with remarkable values in panels of Non-Small Cell Lung Cancer, Melanoma and Leukemia, with GI50 range of 1.15-7.33 μM and 0.167-7.59 μM, respectively, and suitable LC 50 with values greater than 100 μM.